News

Shultz discusses the impact of lotilaner ophthalmic solution 0.25% to treat active Demodex blepharitis in patients with meibomian gland dysfunction.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

Miranti shared 2025 acne and rosacea trends, as well as an overlapping treatment option for patients with both conditions, at New Wave Dermatology.

Abramson's presented operation indicates that Coats disease can manifest bilaterally and is potentially caused by multiple independent genes.

Williams discusses her takeaways from the 2025 Envision conference and her expectations for the future of both ophthalmology and its practitioners.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

A post-hoc analysis of SURMOUNT-OSA highlights tirzepatide’s consistent benefit across all baseline OSA severity groups.

The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

Nearly all treated patients received glucocorticoids, but many quickly needed later-line therapies, especially those with non-incident pulmonary sarcoidosis.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

Olezarsen shows promising results in reducing triglyceride levels for patients with moderate hypertriglyceridemia, offering hope for better cardiovascular health.

LED BLU-U, used in combination with LEVULAN KERASTICK, is capable of treating minimally to moderately thick actinic keratoses.

At 2025 New Wave Dermatology, HCPLive spoke with Miranti on treating the 4 pillars of pathogenesis, including sebum production, inflammation, and more.

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.

In this ATS 2025 interview, Arthur Reingold, MD, was asked about the effects of the COVID-19 pandemic on immunization rates as well as pulmonologists’ role.

These data from ATS 2025 point to climate change as a potential influence on the burden associated with obstructive sleep apnea (OSA).

Pande explains findings from his research on immunosuppression in interstitial lung disease suggesting this treatment does not affect fibrosis progression.

Over 60% of patients admitted to the ICU with ARF experienced some degree of sleep disturbance after admission.

In this interview at ATS 2025, Reingold highlighted his presentation on the global immunization divide and overcoming barriers to universal vaccine coverage.

These data, presented at ATS 2025, highlight the efficacy results of methotrexate when compared to prednisone for pulmonary sarcoidosis.

New research sheds light on improved waitlist outcomes after new allocation guidelines for lung transplants prioritizing medical urgency were implemented.

At 2025 New Wave Dermatology, Zirwas highlights the most useful dermatology studies from the past 2 years, covering AD misdiagnosis, alopecia, contact dermatitis, and more.

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.